Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129,594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12 inhibitor.
Zhang Y, Zhu X, Zhan Y, Li X, Liu C, Zhu Y, Zhang H, Wei H, Xia Y, Sun H, Liu Y, Lai X, Gong Y, Liu X, Li Y, Ding Y, Zhong D. Zhang Y, et al. Among authors: zhang h. Br J Clin Pharmacol. 2020 Sep;86(9):1860-1874. doi: 10.1111/bcp.14296. Epub 2020 Jun 17. Br J Clin Pharmacol. 2020. PMID: 32267573 Free PMC article. Clinical Trial.
Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium-glucose co-transporter-2 inhibitor, in Chinese people with type 2 diabetes mellitus.
Li X, Zhu X, Liu J, Li Q, Zhang H, Li C, Wu M, Gao L, Wen H, Li X, Tang X, Liu L, Ding Y. Li X, et al. Among authors: zhang h. Diabetes Obes Metab. 2020 Dec;22(12):2316-2324. doi: 10.1111/dom.14156. Epub 2020 Sep 2. Diabetes Obes Metab. 2020. PMID: 32744380 Clinical Trial.
Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial.
Wu M, Li X, Yang D, Wang M, Zhang H, Li C, Mai J, Yang L, Qi Y, Yu JC, Yang X, Wang Z, Gu C, Ding Y. Wu M, et al. Among authors: zhang h. BioDrugs. 2023 Jan;37(1):89-98. doi: 10.1007/s40259-022-00563-5. Epub 2022 Nov 22. BioDrugs. 2023. PMID: 36417156 Free PMC article. Clinical Trial.
The effect of a single escalating dose of long-acting recombinant human follicle-stimulating hormone Fc fusion protein (KN015) on healthy, pituitary-suppressed women: first-in-human and randomized study on its pharmacokinetics, pharmacodynamics, and tolerability.
Zhang H, Fan Y, Gao L, Wang B, Xu T, Wu M, Liu J, Zhu X, Li X, Chen H, Li C, Wang M, Liu C, Mao Y, Yang M, Ding Y. Zhang H, et al. Expert Opin Investig Drugs. 2022 Nov;31(11):1255-1263. doi: 10.1080/13543784.2022.2151434. Epub 2022 Dec 20. Expert Opin Investig Drugs. 2022. PMID: 36537742 Clinical Trial.
Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial.
Jia H, Mai J, Wu M, Chen H, Li X, Li C, Liu J, Liu C, Hu Y, Zhu X, Jiang X, Hua B, Xia T, Liu G, Deng A, Liang B, Guo R, Lu H, Wang Z, Chen H, Zhang Z, Zhang H, Niu J, Ding Y. Jia H, et al. Among authors: zhang z, zhang h. BMC Med. 2023 Mar 16;21(1):98. doi: 10.1186/s12916-023-02814-w. BMC Med. 2023. PMID: 36927420 Free PMC article. Clinical Trial.
ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial.
Hu Y, Li H, Zhang H, Chen X, Chen J, Xu Z, You H, Dong R, Peng Y, Li J, Li X, Wu D, Zhang L, Cao D, Jin H, Qiu D, Yang A, Lou J, Zhu X, Niu J, Ding Y. Hu Y, et al. Among authors: zhang l, zhang h. Nat Commun. 2023 Oct 12;14(1):6409. doi: 10.1038/s41467-023-42162-0. Nat Commun. 2023. PMID: 37828034 Free PMC article. Clinical Trial.
129,594 results
You have reached the last available page of results. Please see the User Guide for more information.